Steep Hill Inc. to Acquire Lir Life Sciences in Strategic Reverse Takeover

Steep Hill Inc ( (TSE:STPH) ) has provided an announcement.

Steep Hill Inc. has signed an agreement to acquire Lir Life Sciences Inc., a private biopharmaceutical company focused on developing innovative therapies for obesity and metabolic disorders. This acquisition, structured as a reverse takeover, involves the issuance of over 136 million common shares of Steep Hill, and is expected to enhance Steep Hill’s position in the biopharmaceutical sector while offering Lir access to public markets. The acquisition aims to leverage Lir’s advanced transdermal drug delivery system to potentially offer a needle-free alternative for complex biologics, aligning with the increasing demand for scalable obesity treatments.

More about Steep Hill Inc

Steep Hill Inc. operates in the cannabis industry, focusing on providing lab testing services and technology for the cannabis sector. The company is dedicated to ensuring product safety and quality through its comprehensive testing solutions.

YTD Price Performance: 200.0%

Average Trading Volume: 78,883

Technical Sentiment Consensus Rating: Hold

Current Market Cap: C$970.7K

For detailed information about STPH stock, go to TipRanks’ Stock Analysis page.